Inhaled Ibuprofen to Treat COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
Summary
- Conditions
- Coronavirus Infection
- Respiratory Disease
- SARS (Disease)
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is an expanded compassionate use program for patients infected with SARS-CoV-2. All patients or their legally authorized representative must provide written informed consent and the patient will be examined to assess their eligibility. Eligible patients will receive inhalation ibuprofen ate three times a day, plus standard care, until the patient became negative, or their physician considers enough or the patient requested to stop.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04382768
- Collaborators
- National Council of Scientific and Technical Research, Argentina
- Centro de Excelencia en Productos y Procesos Córdoba
- Investigators
- Study Director: Dante M Beltramo, PhD Centro de Excelencia en Productos y Procesos Córdoba
Get Well Soon